MASI 38.31 Masimo Corp $MASI added to my watch

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Preserving Our Natural Chompers Digging into the details of endodontic care, you realize how it's the unsung hero in the dental world. And let's face it, teeth don't get happier on their own when there's a problem on the inside. Dr. Christopher Joubert, a wiz on the endodontic front, spills the beans over at HelloNation about how essential these practices are in keeping...

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...

The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...

Echoes from Berlin IFA 2026 in Berlin was a cacophony of innovation, as OneOdio wrapped up its showcase with a bang. Boasting interactive activities and live DJ sets, the event echoed OneOdio's drive to meld advanced audio technology with the pulsating needs of music pros and everyday listeners. You couldn’t miss the excitement in the air at Booth 217. Tech Unplugged:...

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Pfizer's BRAFTOVI Shows Improved Results in Cancer Treatment Today, Pfizer Inc. announced significant findings from a Phase 3 clinical trial named BREAKWATER. This trial investigated the combination of BRAFTOVI (encorafenib) with cetuximab and mFOLFOX6 in patients suffering from BRAF V600E-mutant metastatic colorectal cancer (mCRC). These results, which are particularly...

Nurix Therapeutics Completes Major Stock Offering Nurix Therapeutics, Inc. (NASDAQ: NRIX), a leading clinical-stage biopharmaceutical company, has successfully concluded its recent underwritten registered offering, raising an impressive $250 million through the sale of 24,485,799 shares of common stock at a price of $10.21 per share. This substantial financial boost...

Circle Internet Group: Analyst Insights Before Q2 Earnings Circle Internet Group (CRCL) is gearing up to announce its second-quarter earnings, exciting investors and market watchers alike. This highly anticipated announcement is expected to provide valuable insights into the company's performance and future prospects. Expected Earnings and Revenue Figures Analysts predict...

Nayax Brings Advanced Fuel Management to Tesco's Fleet In a significant development for fleet management in the UK, Nayax Ltd. (NASDAQ: NYAX; TASE: NYAX), a leading provider of commerce enablement solutions, has announced the deployment of its innovative EasyFuelPlus fuel management system. This initiative will transform the way Tesco, a prominent multinational retailer,...

PainReform's Strategic Move into the Clean Energy Market PainReform Ltd. (NASDAQ: PRFX) has successfully completed its acquisition of DeepSolar, a company specializing in AI-driven solar analytics. This significant step allows PainReform to explore new growth opportunities in the clean energy sector and enhance its technological capabilities. By integrating DeepSolar’s...